RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Fit24+ for Obesity and Type 2 Diabetes

Hispanic adolescents are disproportionately burdened by type 2 diabetes (T2D). Social determinants of health (SDoH) serve as barriers to behavior change and participation in disease prevention efforts, especially among vulnerable adolescents.

Official registry: https://clinicaltrials.gov/study/NCT06943001 · Baylor College of Medicine · enrollment listed as 40

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Fit24+. The registry lists allocation as randomized. Hispanic adolescents are disproportionately burdened by type 2 diabetes (T2D).

They plan to enroll about 40 people at Houston. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents

Interventions: Fit24+

Primary outcome (registry wording): Feasibility

Who it is for (from inclusion criteria)

Ages 14 Years to 16 Years
Self-report as Hispanic
obese, defined as body mass index percentile (body-mass index (BMI)%) ≥ 95th percentile
ages of 12-16 years
owns his or her own cellphone

Who the registry excludes

Taking a medication (i.e. steroids) or diagnosed with a condition (i.e. sleep apnea) that influences activity, sleep, and/or cognition
Recent hospitalization or injury that prevents normal physical activity
Currently enrolled in an exercise program or currently using a personal activity monitoring device like Fitbit
Taking medications or diagnosed with a condition that influences activity, glucose metabolism, and/or cognition

Public study contact (from the registry)

Erica Soltero, PhD

402-910-0832

soltero@bcm.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine — Houston, Texas (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseSan Antonio, Texas

Not a traditional drug phase: testing Dapagliflozin for Diabetes Mellitus, Type 2

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

NCT02969798 · Official ClinicalTrials.gov record · The University of Texas Health Science Center at San Antonio

RecruitingNot a traditional drug phaseBuffalo, New York

Blood Collection Biorepository for Liver Disease Research

The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.

NCT03025074 · Official ClinicalTrials.gov record · State University of New York at Buffalo

FAQ about this NCT record

Is NCT06943001 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06943001?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06943001?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary